Head-to-head study demonstrating Gilotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology

• LUX-Lung 7 trial showed afatinib significantly reduced the risk of lung cancer progression and   treatment failure as well as increased overall response rate compared to gefitinib without   compromising overall health-related quality of life, safety and tolerability • Results provide oncologists who treat patients with EGFR mutation-positive lung cancer with   important information for clinical practice
Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news